Constituent ratio and changing trend of non-infectious liver diseases in The Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018

He TingTing; Jing Jing; Bo ZhaoFang; Zou ZhengSheng; Song XueAi; Wang JiaBo; Xiao XiaoHe

doi:10.3969/j.issn.1001-5256.2020.08.019

Volume 36 Issue 8

Aug. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(8): 1773-1777

PDF( 2340 KB)

Constituent ratio and changing trend of non-infectious liver diseases in The Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018

DOI: 10.3969/j.issn.1001-5256.2020.08.019

The Fifth Medical Center of Chinese PLA General Hospital

Research funding:

Published Date: 2020-08-20

Abstract

Abstract

Objective To investigate the constituent ratio and changing trend of four common types of non-infectious liver diseases in our hospital from 2002 to 2018.Methods Medical records were collected from 37 973 patients with non-infectious liver diseases who were admitted to The Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018,and according to the first diagnosis listed in the first page of discharge medical records,14 971 patients had alcoholic liver disease,11 406 had drug-induced liver injury,1776 had nonalcoholic fatty liver disease,and 9820 had autoimmune liver diseases.The distribution characteristics of age and sex and the changing trend were analyzed.The chi-square test was used for comparison of categorical data between groups.Results The patients with drug-induced liver injury accounted for 30.04% of the patients with common non-infectious liver diseases,and it ranked only second to alcoholic liver diseases in all four types.The proportion of patients with drug-induced liver injury among the hospitalized patients with liver diseases tended to increase before 2011,and this constituent ratio showed a trend of transient reduction after 2012.There was a significant difference in sex distribution between the patients with different ages(χ2=113.087,P<0.05).The age of onset was mainly 40-49 years in male patients and50-59 years in female patients.There were significant differences in the age distribution of drug-induced liver injury between the male and female patients hospitalized in different years(χ2=369.252 and 663.490,both P<0.05).There was no significant change in the range of peak age of onset in male patients,while in female patients,the range of peak age of onset showed an aging trend from 40-49 years to50-59 years in the recent 6 years.Conclusion Drug-induced liver injury has become a major part of non-infectious liver disease and often occurs in middle-aged and elderly women.The prevention,control,diagnosis,and treatment of drug-induced liver injury should be taken seriously,especially medication guide and education for middle-aged and elderly women,and it is recommended to strengthen the monitoring of liver function during medication.
- chemical and drug induced liver injury,
- liver diseases,alcoholic,
- non-alcoholic fatty liver disease

FullText(HTML)

References(27)

References

[1] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．酒精性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):939-946.

[2] DANAN G,BENICHOU C. Causality assessment of adverse reactions to drug-I. A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injury[J]. J Clin Epidemiol,1993,46(11):1323-1330.

[3] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.

[4] Branch of Hepatobiliary Diseases,China Association of Chinese Medicine,Branch of Chinese Patent Medicine,China Association of Chinese Medicine. Guidelines for the clinical management of herb-induced liver injury[J]. J Clin Hepatol,2016,32(5):835-843.(in Chinese)中华中医药学会肝胆病分会，中华中医药学会中成药分会．中草药相关肝损伤临床诊疗指南[J]．临床肝胆病杂志，2016,32(5):835-843.

[5] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[6] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.

[7] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

[8] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary sclerosing cholangitis(2015)[J]. J Clin Hepatol,2016,32(1):23-31.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性硬化性胆管炎诊断和治疗专家共识(2015)[J]．临床肝胆病杂志，2016,32(1):23-31.

[9] Cooperative Group of Investigation of Alcohol Dependence and Related Issues. A collaborative study on alcohol dependence among the populations of 4 occupations in 9 cities of China:I.Methodology and prevalence rate[J]. Chin Mental Health J,1992,6(3):112-115,142.(in Chinese)酒精依赖与有关问题调查协作组．中国9个城市4种职业人群酒精依赖协作研究(一)方法学及患病率[J]．中国心理卫生杂志，1992,6(3):112-115,142.

[10] Cooperative Group of Investigation of Alcohol Dependence and Related Issues. A collaborative study on alcohol dependence among the populations of 4 occupations in 9 cities of China:II.Harm of alcohol dependence on mental,physical,and social functions[J]. Chin Mental Health J,1992,6(3):116-117,136.(in Chinese)酒精依赖与有关问题调查协作组．中国9个城市4种职业人群酒精依赖协作研究(二)酒精依赖对精神、躯体和社会功能的危害[J]．中国心理卫生杂志，1992,6(3):116-117,136.

[11] CHEN SL,MENG XD,WANG BY,et al. An epidemiologic survey of alcoholic liver disease in some cities of Liaoning Province(2010)[J]. J Prac Hepatol,2010,13(6):428-435.(in Chinese)陈士林，孟晓丹，王炳元，等．辽宁省部分城市酒精性肝病流行现状调查[J]．实用肝脏病杂志，2010,13(6):428-430,435.

[12] WANG H,MA L,YIN Q,et al. Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China[J]. Alcohol Clin Exp Res,2014,38(4):1035-1041.

[13] HUANG SL,DAI SQ,ZHANG XH,et al. An epidemiological investigation of alcoholic liver disease in Hunan Province,China[J]. J Chin Physician,2005,7(3):426-427.(in Chinese)黄顺玲，戴水奇，张雪红，等．湖南省酒精性肝病流行病学调查概况[J]．中国医师杂志，2005,7(3):426-427.

[14] LIU JJ,JIAO Y,ZHANG HP. An epidemiological investigation of alcoholic liver disease[J]. J Mod Med Health,2010,26(10):1590-1591.(in Chinese)刘江静，焦洋，张宏萍．酒精性肝病的流行病学调查[J]．现代医药卫生，2010,26(10):1590-1591.

[15] LU XL,TAO M,LUO JY,et al. Epidemiology of alcoholic liver diseases in Xi’an[J]. World Chin J Dig,2003,11(6):719-722.(in Chinese)鲁晓岚，陶明，罗金燕，等．西安酒精性肝病流行病学[J]．世界华人消化杂志，2003,11(6):719-722.

[16] National Cooperative Group of Alcoholic Liver Disease Investigation. Management of malignant biliary hilar obstruction with multiple stents[J]. Chin J Dig,2007,27(4):231-234.(in Chinese)全国酒精性肝病调查协作组．全国酒精性肝病的多中心调查分析[J]．中华消化杂志，2007,27(4):231-234.

[17] SHEN T,LIU Y,SHANG J,et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology,2019,156(8):2230-2241.

[18] NAVARRO VJ,BARNHART HX,BONKOVSKY HL,et al. 167herbal and dietary supplement induced hepatotoxicity in the U. S.[J]. Gastroenterology,2012,142(5):S-41.

[19] AKEMI T,YASUNI N,KOUICHI T,et al. Comparison of liver biopsy findings with the digestive disease week Japan 2004scale for diagnosis of drug-induced liver injury[J]. Mediators Inflamm,2015,2015:1-9.

[20] CHALASANI N,HAYASHI P,BONKOVSKY H,et al. ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966,quiz 967.

[21] Chinese Society of Tuberculosis,Chinese Medical Association.Expert recommendations on the diagnosis and treatment of liver injury induced by antitubercular agents[J]. Chin J Tuberc Respir Dis,2013,36(10):732-736.(in Chinese)中华医学会结核病学分会．抗结核药所致药物性肝损伤诊断与处理专家建议[J]．中华结核和呼吸杂志，2013,36(10):732-736.

[22] LI YJ,QI H,SHEN C,et al. Research advances in susceptibility to hepatotoxicity induced by antitubercular agents[J]. Chin J Evid Based Pediatr,2016,11(4):309-316.(in Chinese)李颖佳，綦辉，申晨，等．抗结核药物致肝毒性易感性研究进展[J]．中国循证儿科杂志，2016,11(4):309-316.

[23] WANG JY,TSAI CH,LEE YL,et al. Gender-dimorphic impact of PXR Genotype and haplotype on hepatotoxicity during antituberculosis treatment[J]. Medicine(Baltimore),2015,94(24):e982.

[24] ZHU JZ,ZHOU QY,WANG YM,et al. Prevalence of fatty liver disease and the economy in China:A systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.

[25] LEUNG JC,LOONG TC,WEI JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology,2017,65(1):54-64.

[26] WANG Y,WANG B,SHEN F,et al. Body mass index and risk of primary liver cancer:A meta-analysis of prospective studies[J]. Oncologist,2012,17(11):1461-1468.

[27] WONG VW,WONG GL,YEUNG JC,et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J]. Hepatology,2016,63(3):754-763.

Relative Articles

[1]	Zhili XIAO, Chenxia LU, Danni ZHOU, Zhuangzhuang CHEN, Mingzhong XIAO, Xiaodong LI. Role of lipophagy in the prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(7): 1450-1458. doi: 10.12449/JCH240725
[2]	Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[3]	Chenlu ZHAO, Cheng ZHOU, Dongfang SHANG, Sutong LIU, Junhao SHI, Xiaojie WANG, Wenxia ZHAO. Influence of white fat browning on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(4): 909-914. doi: 10.3969/j.issn.1001-5256.2023.04.025
[4]	Rui JIN, Xiaoxiao WANG, Feng LIU, Huiying RAO. Research advances in pharmacotherapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1634-1640. doi: 10.3969/j.issn.1001-5256.2022.07.033
[5]	Luo YuXin, Guo JinBo, Zhang XiaoLan. Research advances in the role of macrophages in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 680-683. doi: 10.3969/j.issn.1001-5256.2020.03.046
[6]	YU Di, YANG XuYao, ZHAO JinHan, CHUAN LiXue, CHANG Jiang. Association between anxiety and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2589-2592. doi: 10.3969/j.issn.1001-5256.2020.11.043
[7]	WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
[8]	Yang XuYao, Yu Di, Zhao JinHan, Chuan LiXue, Chang Jiang. Association between nonalcoholic fatty liver disease and depression[J]. Journal of Clinical Hepatology, 2020, 36(1): 201-204. doi: 10.3969/j.issn.1001-5256.2020.01.048
[9]	Ceng Jing, Fan JianGao. Clinical significance of renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1205-1207. doi: 10.3969/j.issn.1001-5256.2020.06.002
[10]	Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
[11]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[12]	Jiang YuZi, Nie HongMing, Wang Rong. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(11): 2588-2591. doi: 10.3969/j.issn.1001-5256.2019.11.044
[13]	Gong Hang, Li LiangPing. Noninvasive diagnosis of progressive nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 406-410. doi: 10.3969/j.issn.1001-5256.2019.02.038
[14]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[15]	Cao HaiXia, Fan JianGao. Alcoholic liver disease with nonalcoholic fatty liver disease and obesity[J]. Journal of Clinical Hepatology, 2019, 35(3): 478-480. doi: 10.3969/j.issn.1001-5256.2019.03.005
[16]	Suo YuHong, Liu JinChun. Research advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2232-2236. doi: 10.3969/j.issn.1001-5256.2018.10.038
[17]	Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
[18]	Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
[19]	Lu BingJie, Chen Xi, Sun MingYu. Application of lipid-regulating drugs in prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2444-2448. doi: 10.3969/j.issn.1001-5256.2017.12.043
[20]	Guo YinYan, Li Peng. A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 279-280+301.

Supplements(0)

Cited By

Cited by

Periodical cited type(9)

1.	任晓蕾，詹轶秋，张春燕，黄琳，张晓红. 326例药物相关肝脏不良反应病例分析. 中国医院药学杂志. 2024(14): 1693-1696 .
2.	何淑莹，梁文汉，邵考珍. 某医院药物性肝损伤患者的临床特征及其保肝药合理性分析. 临床合理用药. 2024(33): 174-177 .
3.	王翠，王芬，陈林. 遂宁市中心医院2006～2022年常见非感染性肝病分布特征及变化趋势分析. 现代消化及介入诊疗. 2023(05): 573-577 .
4.	何婷婷，梁庆升，王丽苹，梁龙鑫，李筱涵，崔延飞，景婧，柏兆方，宫嫚，王睿林. 整合证据链、Roussel Uclaf因果关系评价法、结构化专家观点程序对药物性肝损伤的诊断效用分析. 临床肝胆病杂志. 2022(01): 141-147 . 本站查看
5.	路燕，陈明月，郑秀良，雷宇. 185例药物性肝损伤患者的临床特征分析. 安徽医学. 2022(03): 308-313 .
6.	方建凯，李孝楼，江晓燕，罗琼. 慢性乙型肝炎住院患者近5年的构成比分析. 福建医药杂志. 2022(05): 84-86 .
7.	崔今姬，金京哲，穆振斌. 化疗药物对胃肠道恶性肿瘤患者肝损伤的影响因素分析. 社区医学杂志. 2022(19): 1100-1106 .
8.	王瑜，仇丽霞，范作鹏，宋静静，张晶，展玉涛. 不同类型的急性药物性肝损伤患者临床特征比较. 临床肝胆病杂志. 2021(03): 632-635 . 本站查看
9.	李琰，刘文成，常冰. 白藜芦醇对酒精性肝病保护作用机制的研究进展. 中国医师杂志. 2021(11): 1753-1755 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1788) PDF downloads(147)

Constituent ratio and changing trend of non-infectious liver diseases in The Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018

DOI: 10.3969/j.issn.1001-5256.2020.08.019

Abstract

References

Relative Articles

Cited by

Periodical cited type(9)

Other cited types(2)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content